Henry O. Gosebruch - Mar 1, 2022 Form 4/A - Amendment Insider Report for AbbVie Inc. (ABBV)

Signature
Steven L. Scrogham, attorney-in-fact for Henry O. Gosebruch
Stock symbol
ABBV
Transactions as of
Mar 1, 2022
Transactions value $
-$3,682,189
Form type
4/A - Amendment
Date filed
5/20/2022, 05:00 PM
Date Of Original Report
Mar 2, 2022
Previous filing
Mar 1, 2022
Next filing
May 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Sale -$2.31M -15.7K -20.04% $146.81 62.8K Mar 1, 2022 In trust F1
transaction ABBV Common Stock, $0.01 par value Sale -$763K -5.17K -8.23% $147.60 57.6K Mar 1, 2022 In trust F2
transaction ABBV Common Stock, $0.01 par value Sale -$595K -4K -6.94% $148.71 53.6K Mar 1, 2022 In trust F3
transaction ABBV Common Stock, $0.01 par value Sale -$14.9K -100 -0.19% $149.38 53.5K Mar 1, 2022 In trust F4, F5, F7
holding ABBV Common Stock, $0.01 par value 41.6K Mar 1, 2022 Direct F7
holding ABBV Common Stock, $0.01 par value 3.46K Mar 1, 2022 Profit sharing trust F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F6 Balance in AbbVie Savings program as of January 31, 2022.
F7 Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error.

Remarks:

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).